Much in the pipeline and negotiations with ‘famous’ names are ongoing for Hemogenyx Pharmaceuticals
“We’re about making drugs to treat patients, save lives and everything else will follow…including the share price”
The summer heat is intense, the markets celebrated ‘Freedom Day’ with a meltdown, but while traders are hot and bothered, the scientists at Hemogenyx Pharmaceuticals are cooly and cheerfully making progress with their clinical candidates, and doing so at speed.
However, the company will not be rushed into making announcements until their findings, of which there are several, are “bullet proof” in terms of being protected, repeatable and reproducible.
Founder and chief executive Dr Vladimir Sandler says the main thrust of the company is concentrating on what it can achieve in terms of moving its product candidates into clinical trials. “Without it we can not move to the next stage.”
“Our goal is to go into and to open an IND (investigational new drug), and go into clinical trials with at least one product candidate, and at this point the most realistic product candidate that will probably go into clinical trials will be CART T. That’s where our attention is, and this is what we’re doing every day 24/7.”
Hemogenyx has constructed Chimeric Antigen Receptor (CAR) programmed T cells, termed HEMO-CAR-T, for the potential treatment of Acute Myeloid Leukemia. CAR-T therapy is a treatment in which a patient’s own T cells, a type of immune cell, are modified to recognise and kill the patient’s cancer cells.
Whilst progress with CART T may define the company in the short term, as Vlad explains to Sarah Lowther there is much in the pipeline and negotiations with ‘famous’ names are ongoing.
Read the latest corporate presentation referenced in the podcast here
Follow the company on Twitter @HemogenyxPharma
The author was remunerated but does not hold shares in the company